Top Markets
#1 Black Phoenix Black Phoenix +356.02%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.21%
#4 Akedo Akedo +48.10%
#5 Acurast Acurast +34.08%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.41%
#7 BasedHype BasedHype +25.78%
#8 Avantis Avantis +23.46%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.54%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Destiny Pharma plc Destiny Pharma plc

Destiny Pharma plc

DEST
株式のランク #41142
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in... Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
株価
$0.04082105
最終同期: 2024-08-12
時価総額
$39.09K
変化（1日）
-19.83%
変化（1年）
0.00%
国
GB
取引 Destiny Pharma plc (DEST)

カテゴリー

Healthcare
Destiny Pharma plc（DEST）の収益
Dec 2023 時点の収益 TTM: $1.06M
Destiny Pharma plc の最新の財務報告によると、現在の収益 (TTM) は $1.06M です。2022 年には $186.91K の収益があり、これは 2021 年の $182.56K と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Destiny Pharma plc の収益履歴（2013 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $1.06M 0.00%
2023 $1.06M 466.34%
2022 $186.91K 2.39%
2021 $182.56K 972.50%
2020 $17.02K -95.80%
2019 $405.66K 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,192,485.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 568,715.68%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 955,040.28%
BE